Rabbit Polyclonal CPI-17 phospho T38 antibody. Suitable for WB, IHC-P and reacts with Mouse, Human samples. Cited in 5 publications. Immunogen corresponding to Synthetic Peptide within Human PPP1R14A phospho T38 aa 1-100.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
WB | IHC-P | |
---|---|---|
Human | Expected | Tested |
Mouse | Tested | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
Inhibitor of PPP1CA. Has over 1000-fold higher inhibitory activity when phosphorylated, creating a molecular switch for regulating the phosphorylation status of PPP1CA substrates and smooth muscle contraction.
CPI17, PPP1INL, PPP1R14A, Protein phosphatase 1 regulatory subunit 14A, 17 kDa PKC-potentiated inhibitory protein of PP1, Protein kinase C-potentiated inhibitor protein of 17 kDa, CPI-17
Rabbit Polyclonal CPI-17 phospho T38 antibody. Suitable for WB, IHC-P and reacts with Mouse, Human samples. Cited in 5 publications. Immunogen corresponding to Synthetic Peptide within Human PPP1R14A phospho T38 aa 1-100.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride
ab52174 detects endogenous levels of CPI17a only when
phosphorylated at threonine 38.
ab52174 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
CPI-17 also known as Protein Kinase C-Potentiated Inhibitor Protein-17 is a protein that acts as a myosin phosphatase inhibitor. It has a molecular mass of approximately 17 kDa. Expressed in various tissues including smooth muscle heart and brain CPI-17 plays an essential role in regulating smooth muscle contractility. The protein modulates the phosphorylation state of myosin light chains by inhibiting myosin phosphatase activity impacting muscle contraction dynamics.
CPI-17 influences smooth muscle function by modulating the phosphorylation status of myosin light chains. It is not a component of larger protein complexes but interacts directly with myosin phosphatase. The precise regulation of myosin light chain phosphorylation by CPI-17 is critical for maintaining smooth muscle contractile responses affecting functions such as vasoconstriction and peristalsis.
CPI-17 plays an important role in the RhoA/ROCK signaling pathway which is key to controlling smooth muscle tension and motility. Through this pathway CPI-17 interacts closely with proteins like ROCK (Rho-associated coiled-coil containing protein kinase). Additionally CPI-17 is associated with the PKC (Protein Kinase C) pathway where its phosphorylation status and inhibitory activity are regulated by PKC enzymes emphasizing its role in cellular signal transduction.
CPI-17 is implicated in conditions such as hypertension and asthma where dysregulated smooth muscle contractility is a factor. In hypertension CPI-17's interaction with the PKC pathway suggests a substantial influence on blood vessel tension while in asthma altered CPI-17 activity affects airway smooth muscle contraction. The link between CPI-17 and PKC proteins under these conditions provides insight into potential therapeutic targets for managing these diseases.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab52174 at 1/50 dilution staining CPI-17 in human breast carcinoma by Immunohistochemistry, paraffin embedded tissue, in the presence (right image) and absence (left image) of the immunising peptide.
Western blot analysis of extracts from RAW264.7 cells, using CPI-17 (Phospho-Thr38) (ab52174)Antibody. The lane on the right is treated with the synthesized peptide.
All lanes: Western blot - Anti-CPI-17 (phospho T38) antibody (ab52174)
Predicted band size: 17 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com